A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells

Akito Nakagawa,†‡‡ Michele Ferrari,† Grigori Schleifer,† Marissa K. Cooper,† Chen Liu,† Binglan Yu,† Lorenzo Berra,† Elizabeth S. Klings,† Ronni S. Safo,§ Qiukan Chen, II Faik N. Musayev,§ Martin K. Safo,§ Osheiza Abdulmalik,∥ Donald B. Bloch,†⊥∥⊥⊥⊥⊥ and Warren M. Zapol⊥⊥⊥⊥

†Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States
‡The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts 02118, United States
§Department of Medicinal Chemistry, The Institute for Structural Biology, Drug Discovery, and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, United States
∥Division of Hematology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, United States
⊥Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States

Supporting Information

ABSTRACT: Sickle cell disease is an inherited disorder of hemoglobin (Hb). During a sickle cell crisis, deoxygenated sickle hemoglobin (deoxyHbS) polymerizes to form fibers in red blood cells (RBCs), causing the cells to adopt “sickled” shapes. Using small molecules to increase the affinity of Hb for oxygen is a potential approach to treating sickle cell disease, because oxygenated Hb interferes with the polymerization of deoxyHbS. We have identified a triazole disulfide compound (4,4′-dithio(1,2,3-triazolyl)disulfide, designated TD-3), which increases the affinity of Hb for oxygen. The crystal structures of carboxy- and deoxy-forms of human adult Hb (HbA), each complexed with TD-3, revealed that one molecule of the monomeric thiol form of TD-3 (5-mercaptop-1H-1,2,3-triazole, designated MT-3) forms a disulfide bond with β-Cys93, which inhibits the salt-bridge formation between β-Asp94 and β-His146. This inhibition of salt bridge formation stabilizes the R-state and destabilizes the T-state of Hb, resulting in reduced magnitude of the Bohr effect and increased affinity of Hb for oxygen. Intravenous administration of TD-3 (100 mg/kg) to C57BL/6 mice increased the affinity of murine Hb for oxygen, and the mice did not appear to be adversely affected by the drug. TD-3 reduced in vitro hypoxia-induced sickling of human sickle RBCs. The percentage of sickled RBCs and the P50 Bohr effect, which exhibits low affinity for oxygen. The affinity of Hb for oxygen is dependent upon pH (the Bohr effect), a property that facilitates the efficient uptake and release of oxygen in vivo: the R-state, which exhibits high-affinity for oxygen, and the T-state, which exhibits low-affinity for oxygen. The affinity of Hb for oxygen is dependent upon pH (the Bohr effect), a property that
arises from the effects of protons on the equilibrium between the T-state and R-state structures.\textsuperscript{17,18} Hb \(\beta\)-chain residues \(\beta\)-His\textsubscript{146} and \(\beta\)-Asp\textsubscript{94} have important roles in the Bohr effect.\textsuperscript{17,18} At low pH, the \(\beta\)-chain imidazole of \(\beta\)-His\textsubscript{146} becomes protonated, resulting in a salt-bridge interaction with the carbonylate of \(\beta\)-Asp\textsubscript{94}. The salt-bridge stabilizes the T-state of Hb and facilitates oxygen release. At higher pH, the salt-bridge is broken, and the allosteric equilibrium shifts toward the R-state, with a concomitant increase in the affinity of Hb for oxygen.

Oxygcnated Hbs (oxyHbs) inhibits the polymerization of deoxyHbs, because fully oxygcnated Hbs does not polymerize.\textsuperscript{2,9,5} Therefore, one approach to the treatment of SCD is to use small molecules to increase the affinity of Hb for oxygen\textsuperscript{19,20} and thereby increase the affinity of Hb for oxygen using HbA that was chemically modified by N-ethylmaleimide (NEM) at \(\beta\)-Cys\textsubscript{93} and a HbA mutant with an alanine replacing \(\beta\)-Cys\textsubscript{93} (Hb C93A). We also studied the crystal structures of COHbA and deoxyHbA, each complexed with TD-3, and showed that modification of the thiol of \(\beta\)-Cys\textsubscript{93} by TD-3 inhibits salt-bridge formation between \(\beta\)-Asp\textsubscript{94} and \(\beta\)-His\textsubscript{146}, resulting in destabilization of T-state Hb, decreased magnitude of the Bohr effect, and increased affinity of Hb for oxygen. Moreover, we demonstrated that intravenous administration of TD-3 to mice increased the affinity of murine Hb for oxygen, and TD-3 reduced hypoxia-induced sickling of human SS RBCs.

**EXPERIMENTAL SECTION**

**Materials.** Di(5-(2,3-dihydro-1,4-benzodioxin-2-yl)-4H-1,2,4-triazol-3-yl)disulfide (TD-1) was purchased from Chem-Partner (Shanghai, China). 4,4′-Di(1,2,3-triazolyl)disulfide hydrate (TD-3) and 5-Mercapto-1H-1,2,3-triazole sodium salt (MT-3) were purchased from TCI America (Portland, OR, USA). N-Ethylmaleimide (NEM) and PEG400 (Catalog No. 202398) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Normal human blood and blood from patients with sickle cell disease (homozygous SS disease) were obtained from volunteers using protocols that were reviewed and approved by Institutional Review Boards (IRB) of the Partners Healthcare Human Research Committee, Boston Medical Center, and the Children’s Hospital of Philadelphia. Outdated donated red blood cells (RBCs) were obtained from the blood bank of the Massachusetts General Hospital and used to obtain HbA. Studies using mice were approved by the Institutional Animal Care and Use Committee of Massachusetts General Hospital.

**Purification of HbA.** RBCs were centrifuged at 3000 rpm for 15 min at 4°C. The supernatant was discarded, and the remaining RBCs were washed three times with an equal volume of saline (aqueous solution of 0.9 wt % sodium chloride). Two equivalents of distilled water (4°C) were added to the washed
RBCs to lyse the cells, and the mixture was centrifuged at 20 000 g for 1 h at 4 °C. The supernatant was collected and centrifuged again (under the same conditions), and the resulting supernatant was collected and dialyzed against Dulbecco’s phosphate buffered saline (PBS, pH 7.4) at 4 °C for 18 h. The dialyzed Hb was passed through 0.2 μm poly(ether sulfone) membrane (Thermo Scientific, Cat. No. 725–2520) to remove protein aggregates. The absorption spectrum of the obtained Hb was measured from 500–700 nm, fitted to a linear combination of pure oxygenated hemoglobin (oxyHb), deoxygenated hemoglobin (deoxyHb), met hemoglobin (metHb), and a baseline using the Solver program (Excel 2013, Microsoft, Redmond, WA, USA) to determine the total concentration of Hb.23

Measurement of the Oxygen Dissociation Curve (ODC) of Purified Hb. The ODC of purified Hb was measured at 37 °C using a HEMOX analyzer (TCS Scientific Corporation, New Hope, PA, USA). TD-1 and TD-3 were dissolved in DMSO, and MT-3 was dissolved in PBS as stock solutions. HbA (20 μM tetramer) was incubated with each of the compounds, which were diluted in PBS containing DMSO (5 vol %) and antifoaming agent (0.2 vol %, TCS Scientific Corporation). After the incubation, the ODC of the samples were measured at 37 °C. In evaluating the Bohr effect of HbA, sodium phosphate buffer (0.1 M phosphate, pH 6, 6.5, 7, 7.5, or 8.0) was used instead of PBS to measure the ODC of Hb with TD-3 (Hb tetramer/TD-3 = 1/6 mol/mol). The partial pressure of oxygen at which 50% of Hb is oxygenated (P50), was determined from the ODC.

Measurement of the ODC of Human RBCs. After obtaining informed consent, blood was collected from healthy volunteers or a sickle disease patient into tubes containing EDTA. The human sickle cell blood was obtained from a single patient who has homozygous SS disease and was treated with hydroxyurea but not chronic blood transfusions. The concentration of Hb in the collected blood was determined using a blood gas analyzer (ABL 800 FLEX, Radiometer America, Brea, CA, USA).

A PEG solution of TD-3 (267 mM) was mixed with PBS (PEG solution of TD-3/PBS = 3/7 v/v) at 37 °C to obtain a stock solution of TD-3 (80 mM of TD-3 or 16 mg/mL of TD-3 hydrate) in PBS with PEG400 (30 vol %). The obtained mixture was filtrated through 0.2 μM poly(ether sulfone) membrane (Catalog No. 725–2520, Thermo Fisher Scientific, Waltham, MA, USA) to remove aggregates, and the filtrate was kept at 37 °C. PBS with PEG400 (30 vol %) was prepared as a control or vehicle for TD-3-treated samples.

The stock solution of TD-3 in PBS with PEG400 (30 vol %) was added to human whole blood, and the mixtures were incubated at 37 °C for 10 min. The molar ratios of TD-3 to Hb tetramer in the mixtures were 0, 1, 2, and 3, and the concentration of PEG400 was 2 vol %. After the incubation, 20 μL of each mixture was diluted with 3 mL HEMOX solution (TCS Scientific Corporation) and 6 μL of the antifoaming agent. HEMOX solution contains N-(Tris(hydroxymethyl))-methyl]-2-aminoethanesulfonic acid (TES, 30 mM), sodium chloride (135 mM), and potassium chloride (5 mM) in water (pH 7.4). The ODCs of the diluted blood samples were measured using a HEMOX analyzer with the sample maintained at 37 °C.

Intravenous Administration of TD-3 to C57BL/6 Mice and Blood Collection from Mice. C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). A micro catheter, consisting of a 30 G BD PrecisionGlide needle (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and PE10 tubing was used to intravenously administer TD-3 or vehicle to mice. The metal part of the needle was snapped and the tip partially slipped into the tubing. The mouse was restrained and anesthetized with sevoflurane (3–3.5 vol %) in air. Once the mouse was asleep, breath rate was monitored continuously. The tail was then punctured until a flash of blood was observed in the catheter. Saline (50 μL) was injected to confirm that there was no resistance to the injection. The syringe was connected to a volume controlled infusion pump (BrainTree Scientific, MA, USA), and the desired volume of the sample was injected at a rate of 30 μL/min. The mouse was kept anesthetized for the duration of the injection. The dose of PEG400 in the vehicle or TD-3 treatment was 1.96 mL/kg. This dose was similar to the maximum dose of PEG400 (2 mL/kg) that can be given to a mouse without causing injury.24 Murine blood was collected before and after the treatment with TD-3 by a tail nick. Drops of blood were collected using a heparinized microhematocrit capillary tube (Fisher Scientific, Pittsburgh, PA, USA).

Measurement of the ODC of Intact Murine RBCs and Murine Hb (as Hemolysate). The ODC of murine whole blood was measured as described above for human RBCs. To measure the ODC of murine Hb, 20 μL of whole blood was mixed with 180 μL of distilled water to prepare murine Hb as hemolysate. The obtained hemolysate was mixed with 2.8 mL of HEMOX solution containing 6 μL of antifoaming reagent. The ODC of the mixture was measured using HEMOX analyzer at 37 °C.

HPLC Analyses of TD-3-Treated Murine Hb. Murine blood was collected before and after intravenous administration of TD-3. The collected blood (20 μL) was mixed with distilled water (180 μL) to lyse RBCs. The lysed cells were centrifuged at 13 000 g for 10 min to remove precipitates, including RBC ghosts. The supernatant was snap frozen in liquid nitrogen and stored at −80 °C until the HPLC measurement. Clarified hemolysates were analyzed for levels of endogenous (unmodified) or modified adduct forms of Hb by HPLC using the Hitachi D-7000 HPLC System (Hitachi Instruments, San Jose, CA, USA) and a weak cation-exchange column (Poly CAT A: 35 mm × 4.6 mm, Poly LC, Columbia, MD, USA). The samples were eluted with a linear gradient of phase B from 0 to 80% (Mobile Phase A: 20 mM Bis-Tris, 2 mM potassium cyanide, pH 6.95; Phase B: 20 mM Bis-Tris, 2 mM potassium cyanide, 0.2 M sodium chloride, pH 6.55), and the eluted samples were detected by absorbance at 410 nm (A410). The percentage of modified Hb was determined by dividing the area of the peak of modified Hb by the area of the peaks produced by both unmodified and modified Hb.

Preparation of NEM-Treated HbA. NEM-treated HbA was prepared according to a previously reported procedure22 with slight modification. HbA (0.6 mM as a tetramer) was mixed with NEM (12 mM) in PBS and incubated at room temperature in air for 1 h. After the incubation, free NEM was removed by passing the mixture through a Sephadex G25 PD-10 column (GE Healthcare Lifesciences, Pittsburgh, PA, USA). NEM-bound HbA, which appeared as a red chromatographic band, was collected, and the concentration of NEM-HbA was determined as described above for HbA.

Purification of Hemoglobin from Knock-in Mice. Mice expressing human Hb with a β chain C93A mutation (HbC93A mice25) and mice expressing wild-type human Hb (HbC93...
mice were kindly provided by Dr. Tim Townes (University of Alabama, Birmingham). An animal lancet (Goldenrod, Medipoint, Mineola, NY, USA) was used to collect blood from the facial vein into a heparinized glass capillary. Hb C93A and wt Hb were purified, and the concentration of Hb was determined as described for HbA above.

**Crystallization, Data Collection, and Structure Determination of CarboxyHb (COHb) and Deoxygenated Hb (deoxyHb) Complexed with TD-3.** To prepare a crystal containing COHbA complexed with TD-3, oxyHbA was vacuumed for 1 h (to remove oxygen), and then carbon monoxide gas was bubbled into the solution. A freshly prepared solution of TD-3 in DMSO was added to COHbA (50 mg/mL) at a one-to-one molar ratio of Hb tetramer to TD-3 and incubated for 1 h to obtain COHbA complexed with TD-3. To prepare a crystal containing deoxyHbA complexed with TD-3, a freshly prepared solution of TD-3 dissolved in DMSO was added to oxyHbA (50 mg/mL) at a one-to-one molar ratio of Hb tetramer to TD-3 and incubated for 1 h. The solution of oxyHbA with TD-3 was subjected to a vacuum for at least 1 h to obtain deoxyHbA complexed with TD-3. The resulting COHbA and deoxyHbA were crystallized in solution containing a high concentration of phosphate and/or sulfate salt (3.2% PEG400 at 2.0 Å for the COHbA complex structure and 19.8%/26.5% at 2.0 Å for the COHbA complex structure and/or CO molecules, as well as water molecules to the protein model, and further refinements resulted in final R factor/Rfree of 19.8%/26.5% at 2.0 Å for the COHbA complex structure and 15.8%/19.7% at 1.7 Å for the deoxyHbA complex structure. Model buildings and corrections were carried out using COOT. In the crystal structure of COHbA complexed with TD-3, the locations of β-Lys144, β-Tyr145, and β-His146 could not be identified because of disorder. The atomic coordinates and structure factors from the COHbA and deoxyHbA complexed with TD-3 have been deposited in the RCSB Protein Data Bank with the accession codes 6BWU and 6BWP, respectively. Detailed crystallographic parameters are reported in Table S1.

**Evaluation of the Ability of TD-3 To Reduce Sickling of SS RBCs in Vitro.** SS blood was collected from many different patients, all of whom had homozygous SS disease. None of the blood donors were treated with hydroxyurea or chronic blood transfusions. The SS blood was suspended in HEMOX solution (100 μL) supplemented with glucose (10 mM) and bovine serum albumin (0.2 wt %) to a final hematocrit of 20%. The suspensions were incubated in a 96-well plate under air in the presence of vehicle (PBS with 30 vol % PEG400) or four different concentrations of TD-3 (0.5, 1.0, 1.5, and 2 mM) at 37 °C for 1 h. The concentration of PEG400 in the mixture of RBCs with vehicle or TD-3 was 2 vol %. The suspensions were exposed to a gas mixture of O2 (4%) and N2 (96%) at 37 °C for 2 h. After the incubation, aliquots (5 μL) of each sample were used to evaluate the sickling of RBCs, and the residual samples were used for HPLC and ODC studies to measure the modified Hb% and the affinity of HbS for oxygen.

After incubation in 4% O2, aliquots (5 μL) of each sample were collected without exposure to air and fixed in 2% glutaraldehyde. Cells were placed on glass microslides (Fiber Optic Center) so as to produce a single layer of cells and subjected to microscopic morphological analysis of bright field images (at 40X magnification) using an Olympus BX40 microscope fitted with an Infinity Lite B camera (Olympus, Center Valley, PA, USA) and Infinity Capture software. The percentage of sickled cells for each condition was determined using the computer-based image analysis system. The percentage of sickled cells (sickled%) induced by hypoxia was determined by subtracting the percentage of cells that were sickle shaped prior to hypoxia from the percentage that appeared sickled after hypoxia.

SS RBCs treated with TD-3 were lysed, and aliquots of the hemolysates were utilized for HPLC and ODC studies. HPLC studies were conducted as described for murine Hb. The ODC of the hemolysates was measured in potassium phosphate buffer (0.1 M phosphate, pH 7.0) supplemented with antifoaming agent at 25 °C using the HEMOX Analyzer.

**Statistics.** Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA). A two-tailed, unpaired t test was used to compare the values of P50 or the percentage of sickled cells at two different concentrations of TD-3. The value of r (= |ΔlogP50/ΔlogHb|) of HbA with and without TD-3 was compared by analysis of covariance (ANCOVA). A two-tailed, paired t test was used to compare the values of P50 before and after the injection of TD-3 to mice. Statistical significance was defined as a p-value of less than 0.05.

**RESULTS**

**Solubility of TD-3 in Aqueous Solution Is Greater than that of TD-1.** Although TD-1 was able to increase the affinity of Hb for oxygen, the further use of this compound is limited by its lack of aqueous solubility. In contrast to TD-1, when a solution of TD-3 was warmed to 37 °C, it was readily soluble in Dulbecco’s phosphate buffered saline (PBS) containing polyethylene glycol (PEG) 400 (30 vol %) at a concentration of 80 mM (compared to 4 mM for TD-1). The increased solubility of TD-3 permits intravenous administration of TD-3.

**TD-3 Increases the Affinity of Human and Murine Hemoglobin and Red Blood Cells for Oxygen.** We tested the ability of TD-3 to alter the affinity of purified Hb for oxygen, under the same conditions that were previously used to evaluate TD-1. In these in vitro studies, TD-3 was dissolved in DMSO and added to HbA (TD-3/Hb tetramer = 0, 1, 2, 4, 1957 DOI: 10.1021/acs.molpharmaceut.8b00108 Mol. Pharmaceutics 2018, 15, 1954–1963
and 6 mol/mol). In the mixture of HbA and TD-3, the concentration of Hb was 20 μM (as Hb tetramer) and the fraction of DMSO was 5 vol %. After a 10 min incubation at 37 °C, the oxygen dissociation curve (ODC) of the mixture was measured and was used to determine the partial pressure of oxygen at which 50% of Hb is oxygenated (P50). Incubation of TD-3 with HbA shifted the ODC to the left with increasing concentrations of TD-3 (Figure 1B), resulting in a marked reduction in P50 of TD-3-treated RBCs was still lower than the P50 of RBCs; 27 ± 0.2 mmHg vs 23 ± 0.2 mmHg, p-value < 0.001). Each data point in C, D, and E represents the mean value, and error bars represent the standard deviation of 4.5 ± 0.07 mmHg (TD-3/Hb tetramer = 6 mol/mol, Figure 1C). The effect of TD-3 on the P50 of HbA was dose-dependent and was similar to that observed with TD-1 (Figure 1C). When the molar ratio of TD-3:HbA tetramer was decreased to 1:1, the P50 of TD-3-treated HbA was still lower than the P50 of HbA alone (TD-3-treated vs DMSO-treated HbA; 16 ± 0.2 mmHg vs 11 ± 0.2 mmHg, p-value < 0.001).

To test the effect of the disulfide bond of TD-3 on the ability of TD-3 to increase the affinity of Hb for oxygen, 5-mercapto-1H-1,2,3-triazole (MT-3) was added to HbA at the same molar ratios as we used to test TD-3. MT-3 is a monomeric thiol form of 1H-1,2,3-triazole (MT-3) was added to HbA at the same molar ratio. Incubation of HbA with MT-3 for 10 min at 37 °C did not alter the P50 of HbA (Figure 1C). These results indicate that, as with TD-1, the disulfide bond in TD-3 is required to increase the affinity of Hb for oxygen.

To test the ability of TD-3 to alter the affinity of intact RBCs for oxygen, TD-3 was dissolved in PBS containing 30 vol % PEG400 and was added to normal human whole blood at increasing molar ratios (TD-3/Hb tetramer = 0, 1, 2, and 3 mol/mol). In the mixture of TD-3 and whole blood, the fraction of PEG400 was 2 vol %. After a 10 min incubation at 37 °C, the mixture was diluted with HEMOX solution, and the ODC of the diluted solution was measured to determine the P50 of the RBCs. Before the administration of TD-3, HPLC analysis of collected murine blood, blood was collected before (as baseline) and 1 h after the administration of TD-3. The collected blood was diluted with HEMOX solution and the ODC of the diluted solution was measured to determine the P50 of the RBCs. One hour after the administration of vehicle, the P50 of the RBCs was not changed from baseline. In mice treated with a low dose of TD-3 (50 mg/kg), there was a trend toward a decrease in the P50 of the RBCs 1 h after administration (baseline vs 1 h; 41 ± 1.5 mmHg vs 39 ± 0.5 mmHg, p-value = 0.064). Administration of a higher dose of TD-3 (100 mg/kg) produced a more substantial shift of the ODC to the left (Figure 2A), reflecting a 19% decrease in the P50 of murine RBCs (baseline vs 1 h; 42 ± 1.3 mmHg vs 34 ± 2.5 mmHg, p-value = 0.011). All of the mice treated intravenously with vehicle or either dose of TD-3 appeared normal 24 h after administration of TD-3.

To investigate the ability of TD-3 to covalently modify Hb in murine blood, blood was collected before and 1 h after the administration of TD-3, and the fraction of Hb that was modified by TD-3 was assessed using cation-exchange HPLC. Before the administration of TD-3, HPLC analysis of collected blood showed a major peak produced by unmodified murine Hb, with a retention time of 4.2 min (Figure S1). HPLC analyses of murine blood collected 1 h after the administration of TD-3 revealed a new peak (Hb modified by TD-3), which had a retention time of 3.7 min (Figure S1C). The percentage of modified Hb was determined by dividing the area of the peaks produced by both unmodified and modified Hb. In mice administered with the lower concentration of TD-3, the percentage of modified Hb was 9.0% ± 2.5 (mean value ± sd). After treatment with the higher concentration of TD-3 (100 mg/kg), the percentage of modified Hb increased to 19% ± 3.9. These results indicate that intravenous administration of TD-3 produces a dose-dependent increase in modified Hb.

Figure 2. Increase of the affinity of murine Hb for oxygen and covalently modified murine Hb by administration of TD-3 (100 mg/kg) to C57BL/6 mice. The oxygen dissociation curve of C57BL/6 murine RBCs (A) and murine hemolysate (B) measured at 37 °C before and 1 h after intravenous administration of TD-3 (100 mg/kg). The effect of time on the P50 of murine Hb (C) and the percentage of modified Hb (D) before and after administration of TD-3. (E) Correlation between the percentage of modified Hb and the change in P50 of the hemolysate. ΔP50% = (P50 at a time point) − (baseline P50)/baseline P50). Each data point in C, D, and E represents the mean value, and error bars represent the standard deviation of the P50 or modified Hb%. Four mice were used in each of the vehicle- and TD-3-treated group.
We investigated the effect of time on both the TD-3-induced change in affinity of murine Hb for oxygen and the percent of murine Hb modified by TD-3. TD-3 (100 mg/kg) or vehicle was administered intravenously to C57BL/6 mice, and blood was collected before and 1, 5, 10, and 24 h after administration. The ODC of the hemolysates was measured to determine the $P_{50}$ values of murine Hb and the hemolysates were also subjected to HPLC to determine the percentage of modified Hb. The $P_{50}$ of murine Hb before the administration of TD-3 was 21 ± 1.0 mmHg. The reduction in the $P_{50}$ of murine Hb was greatest 1 h after treatment (baseline vs 1 h treatment; 21 ± 1.0 vs 18 ± 0.5 mmHg; $p$-value < 0.01; Figure 2B,C), and a decrease in $P_{50}$ was still detected 5 h after administration of TD-3 (baseline vs 5 h treatment; 21 ± 1.0 vs 19 ± 0.6 mmHg; $p$-value < 0.05; Figure 2C). The $P_{50}$ of Hb returned to baseline 10 h after administration of TD-3 (baseline vs 10 h treatment; 21 ± 1.0 vs 21 ± 0.7 mmHg, Figure 2C). The percentage of modified Hb was greatest 1 h after administration of TD-3 (Figure S2B); modified Hb was no longer detected 24 h after administration of TD-3 (Figures S2E and 2D). The percentage of modified Hb was positively correlated with the change in the $P_{50}$ of the batch method.25

Thiol of β-Cys93 Is Required for TD-3 To Increase the Affinity of Hemoglobin for Oxygen. In previous studies, we showed that TD-1 interacted with the thiol of Hb β-Cys93 to increase the affinity of Hb for oxygen. In this study, we used NEM, a small molecule that covalently binds to Hb β-Cys93 to investigate whether TD-3, like TD-1, also interacts with this residue. NEM was added to HbA (NEM/Hb tetramer = 20/1 mol/mol) in PBS and the mixture was incubated at room temperature for 1 h. After incubation, the remaining free NEM was removed from NEM-treated HbA using size exclusion column chromatography. Increasing concentrations of TD-3 were added to NEM-treated HbA (20 μM), and the mixtures were incubated at 37 °C for 10 min. After incubation, the ODC of NEM-treated HbA was measured to determine the $P_{50}$. In the absence of TD-3, the $P_{50}$ of NEM-treated HbA was 7.8 ± 0.6 mmHg. Increasing concentrations of TD-3 did not further reduce the $P_{50}$ of NEM-treated HbA (Figure 3A). When NEM-treated HbA was incubated with TD-3, at a TD-3 to Hb tetramer molar ratio of 6:1, the $P_{50}$ was 8.3 ± 0.2 mmHg. The results suggest that prior modification of the thiol of β-Cys93 by NEM blocks the ability of TD-3 to increase the affinity of Hb for oxygen.

A HbA mutant with an alanine replacing β-Cys93 (HbC93A) was used to further investigate the mechanism by which TD-3 alters the affinity of Hb for oxygen. In these studies, HbC93A was purified from blood that was collected from knock-in mice that exclusively express HbA with β-chain C93A ("HbC93A mice").23 As a control, Hb was purified from blood that was collected from knock-in mice ("HbC93 mice") that express human wild-type HbA ("wt Hb") or HbC93A. The $P_{50}$ values of wt Hb and HbC93A, in the absence of TD-3, were 16 ± 0.1 and 16 ± 0.2 mmHg, respectively. These $P_{50}$ values were similar to the $P_{50}$ of HbA purified from human blood (17 ± 0.3 mmHg). When wt Hb was incubated with TD-3 at a TD-3:Hb tetramer molar ratio of 6:1, the $P_{50}$ of wt Hb was reduced from 16 ± 0.1 to 6.2 ± 0.6 mmHg ($p$-value < 0.001, Figure 3B). This change was similar to that observed using HbA purified from normal human blood (Figure 1c). In contrast, the $P_{50}$ of HbC93A was unchanged by increasing the concentration of TD-3 (Figure 3B). These results, taken together with the results using NEM-treated Hb, support the hypothesis that the thiol of Hb β-Cys93 is required for the ability of TD-3 to increase the affinity of Hb for oxygen.

TD-3 Decreases the Magnitude of the Bohr Effect. The Bohr effect is the pH dependency of the affinity of Hb for oxygen, a property that results from effects of protons on the equilibrium between the T-state and R-state structures.17,18,36–38 The equation $r = ΔlΩlogP50/logpH$ is a measure of the magnitude of the Bohr effect.38 Disrupting the salt-bridge between β-Asp94 and β-His146 destabilizes the T-state of Hb and significantly contributes to decreasing $r$ (making the $P_{50}$ of Hb less dependent on pH).17,18,37,39–42 In previous studies, we showed that treatment of HbA with TD-1 decreases $r$ when compared to untreated HbA (Figure S3), suggesting that TD-1 inhibited salt-bridge formation between β-Asp94 and β-His146.21

We investigated whether TD-3, like TD-1, changes the magnitude of the Bohr effect. HbA in phosphate buffer (phosphate 0.1 M) was treated with TD-3 (TD-3:Hb tetramer = 6/1 mol/mol) at pH 6.0, 6.5, 7.0, 7.5, and 8.0, and the ODC of each sample was measured at 37 °C. Compared to untreated HbA, treatment of HbA with TD-3 decreased $r$ (HbA with TD-3 vs HbA alone; 0.23 ± 0.013 vs 0.37 ± 0.012, $p$-value < 0.001, Figure S3). This result indicates that TD-3 makes the $P_{50}$ of HbA less dependent on pH. As with TD-1, the ability of TD-3 to reduce the pH dependency of the $P_{50}$ of HbA is likely caused by inhibiting salt-bridge formation between β-Asp94 and β-His146.

Crystal Structures of R-State and T-State HbA, Each in a Complex with TD-3 Show a Disulfide Bond between MT-3 and the Thiol of β-Cys93. To further investigate the mechanism by which TD-3 increases the affinity of Hb for oxygen, we determined the crystal structures of COHbA and deoxyHbA, each in a complex with TD-3. DeoxyHbA was prepared from a solution containing oxyHbA by using a vacuum to remove oxygen. COHbA was prepared by adding carbon monoxide to a solution containing deoxyHbA. COHbA and deoxyHbA were each crystallized with a 10-fold molar excess of TD-3 in buffer containing a high concentration of phosphate and/or sulfate salt (3.2–3.4 M) using a modification of the batch method.25

The crystal of COHbA complexed with TD-3 was isomorphous with the crystal of native COHbA (PDB ID: 1LJW23) with the space group P41212, while the crystal of deoxyHbA complexed with TD-3 was isomorphous with the crystal of native deoxyHbA (PDB ID: 2DNZ24) with the space group P21. The crystal structures of COHbA and deoxyHbA were solved using molecular replacement with the respective native structure as a search model.
(1LJW and 2DN2, respectively) were used to phase and refine the respective complexes, and detailed crystallographic parameters are reported in Table S1. The COHbA complexed with TD-3 showed CO molecules binding at all four heme irons. Both structures revealed one molecule of MT-3 (a monomeric thiol form of TD-3) covalently binding at the thiol of β-Cys93 (Figures 4 and S4). The N1 atom of the triazole ring formed a hydrogen-bond interaction with the peptide oxygen atom of β-Ala142 (Figure 4B), while the N2 and N3 atoms of the triazole ring formed water-mediated hydrogen-bond interactions with α-Ser35,α-Thr38,β-Asp94, and β-His143. MT-3 occupied the position of β-Tyr145 in the native COHbA (1LJW) (Figure S5), suggesting that MT-3 causes a significant change in the location of the C-terminus of the β-chain, including β-Lys144, β-Tyr145, and β-His146. The new locations of β-Tyr145 and β-His146 could not be identified because of disorder. The structure of COHbA complexed with TD-3 suggests that the binding of MT-3 at β-Cys93 prevents β-His146 from forming a salt-bridge interaction with β-Asp94 when Hb is converted from the R- to the T-state. Disruption of the salt-bridge interaction explains, in part, the reduced magnitude of the Bohr effect and the increased affinity of Hb for oxygen in the presence of TD-3.

**MT-3 Binds to COHbA and Stabilizes the R-State of HbA.** The crystal structure of COHbA complexed with TD-3 confirms that MT-3 forms a disulfide bond with the thiol of β-Cys93 (Figures S4A and S6). The N3 atom of the triazole ring formed a hydrogen bond with the side chain of β-His146, while the N2 atom of the triazole ring formed a hydrogen bond with the oxygen atom of β-Lys144 (Figure S5B). As noted previously, in native deoxyHbA (e.g., 2DN2, Figure 5C), there is a salt-bridge interaction between β-Asp94 and β-His146, which stabilizes the T-state.33 In deoxyHbA complexed with TD-3, the covalently bound MT-3 at β-Cys93 localized between β-Asp94 and β-His146 and moved the two residues away from each other, preventing the salt-bridge interaction (Figures S5D and S7). The distance between β-Asp94 and β-His146 increased from 3 to 12 Å (native deoxyHbA vs deoxyHbA complexed with TD-3, Figure S5C,D). The disruption of the salt-bridge formation is consistent with the TD-3-induced increase in the affinity of Hb for oxygen and the decrease in the magnitude of the Bohr effect.

**TD-3 Reduces Hypoxia-Induced Sickling of Human SS Red Blood Cells in Vitro.** TD-3 significantly increased the affinity of human SS RBCs for oxygen (Figure 1F,G). To investigate the ability of TD-3 to reduce sickling, SS RBCs were incubated with TD-3 and then exposed to a low concentration of oxygen (hypoxia) to induce sickling. Human SS RBCs (hematocrit ∼20%) were mixed with vehicle or TD-3 (0.5, 1.0, 1.5, and 2 mM) in air and then incubated in a gas mixture of oxygen (4%) and nitrogen (96%) at 37 °C for 2 h. After incubation, SS RBCs were fixed using glutaraldehyde (2%), and the number of sickled cells and normal cells were counted. Treatment of SS RBCs with TD-3 in 4% oxygen reduced the shape of the RBCs from discoid to sickled (Figure 6A) and increased the percentage of sickled cells from 7.4% ± 0.7 (air) to 93% ± 2.5 (mean value ± sd, p-value <0.001, Figure 6A). When SS RBCs were treated with increasing concentrations of TD-3 and then exposed to 4% O₂, the percentage of sickled cells decreased in a dose-dependent manner (Figure 6b–E). At the highest dose of TD-3 tested, the percentage of sickled cells...
In previous studies, we showed that a triazole disulfide compound, TD-1, increased the affinity of Hb for oxygen. The potential use of TD-1 as a drug to treat SCD was limited by the low aqueous solubility of TD-1. In this study, we describe a derivative of TD-1, designated TD-3, that retains the ability to increase the affinity of Hb for oxygen but has increased solubility. Covalent modification of the thiol of $\beta$-Cys93 was required for TD-3 to increase the affinity of Hb for oxygen. Intravenous administration of TD-3 (100 mg/kg) to C57BL/6 mice increased both the affinity of murine RBCs for oxygen and the percentage of modified Hb. TD-3 markedly increased the affinity of SS RBCs for oxygen and reduced hypoxia-induced sickling of RBCs.

To understand the structural basis of how TD-3 decreased the Bohr effect and increased the affinity of Hb for oxygen, we determined the crystal structures of COHbA and deoxyHbA, each complexed with TD-3. The structures revealed that modification of the thiol of $\beta$-Cys93 by MT-3 inhibits the covalent binding of MT-3 to the thiol of Hb,46 the thiol of murine Hb, like human Hb, has $\beta$-Cys9346, the thiol of murine Hb $\beta$-Cys93 could react with TD-3 to make a disulfide bond between MT-3 and $\beta$-Cys93 to increase the affinity of Hb for oxygen. One

---

**DISCUSSION**

In previous studies, we showed that a triazole disulfide compound, TD-1, increased the affinity of Hb for oxygen. The potential use of TD-1 as a drug to treat SCD was limited by the low aqueous solubility of TD-1. In this study, we describe a derivative of TD-1, designated TD-3, that retains the ability to increase the affinity of Hb for oxygen but has increased solubility. Covalent modification of the thiol of $\beta$-Cys93 was required for TD-3 to increase the affinity of Hb for oxygen. Intravenous administration of TD-3 (100 mg/kg) to C57BL/6 mice increased both the affinity of murine RBCs for oxygen and the percentage of modified Hb. TD-3 markedly increased the affinity of SS RBCs for oxygen and reduced hypoxia-induced sickling of RBCs.

To understand the structural basis of how TD-3 decreased the Bohr effect and increased the affinity of Hb for oxygen, we determined the crystal structures of COHbA and deoxyHbA, each complexed with TD-3. The structures revealed that modification of the thiol of $\beta$-Cys93 by MT-3 inhibits the covalent binding of MT-3 to the thiol of Hb,46 the thiol of murine Hb, like human Hb, has $\beta$-Cys93 which, the thiol of murine Hb $\beta$-Cys93 could react with TD-3 to make a disulfide bond between MT-3 and $\beta$-Cys93 to increase the affinity of Hb for oxygen. One
potential limitation to the use of TD-3 as a treatment for SCD is that only a relatively small fraction of the Hb in murine blood was modified by TD-3. One hour after administration of TD-3 (100 mg/kg) the percentage of modified murine Hb increased to only 15–20%. This finding may suggest that TD-3 is insufficiently delivered to Hb in RBCs. Alternatively, it is possible that TD-3 may covalently or noncovalently bind to other molecules (including thiols) in blood, and thus may be unable to reach Hb ψ-Cys93. Modification of TD-3, so as to increase the interaction between the compound’s side chains and amino acids that are adjacent to Hb ψ-Cys93, may improve the specificity of the interaction between the compound and Hb. We anticipate that these changes would increase delivery of the molecule to Hb and would decrease potential off-target effects.

In conclusion, we identified a triazole disulfide compound (TD-3) that covalently modifies the thiol of Hb ψ-Cys93 and increases the affinity of Hb for oxygen. Covalent binding to the thiol of Hb ψ-Cys93 is required for TD-3 to increase the affinity of Hb for oxygen. Structural studies of both COHbA and deoxyHbA suggest that binding of TD-3 to ψ-Cys93 leads to stabilization of the R-state and destabilization of the T-state, resulting in the increased affinity of Hb for oxygen. Intravenous administration of TD-3 (100 mg/kg) to C57BL/6 mice increased the oxygen affinity of Hb; all of the TD-3 treated mice appeared normal 24 h after the administration of TD-3. TD-3 reduced in vitro hypoxia-induced sickling of human SS RBCs. The percentage of sickled RBCs and the PS of human SS RBCs by TD-3 were inversely correlated with the fraction of Hb modiﬁed by TD-3. Taken together, our ﬁndings suggest that TD-3, and related triazole disulfide compounds that bind to Hb ψ-Cys93, may prove to be new treatments for patients with sickle cell disease.

■ ASSOCIATED CONTENT

 Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.molpharmaceut.8b00108.

Crystallographic data and refinement statistics, representative HPLC chromatograms, the effect of TD-3 on the pH dependency, electron density maps, and a comparison of the crystal structure of native COHbA and COHbA complexed with TD-3 (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*anakagawa@mgh.harvard.edu
* wzapol@mgh.harvard.edu

ORCID

Akito Nakagawa: 0000-0002-7047-1735
Martin K. Safo: 0000-0002-9536-1743

Author Contributions

*D.B.B. and W.M.Z. contributed equally to this work.

Notes

The authors declare the following competing financial interest(s): The General Hospital Cooperation has filed a patent related to TD-1 and TD-3. The atomic coordinates and structure factor files have been submitted to the Protein Data Bank under an accession code for COHbA in a complex with TD-3 (PDB ID: 6BWU) and deoxyHbA in a complex with TD-3 (PDB ID: 6BWP).

■ ACKNOWLEDGMENTS

The authors wish to acknowledge T. Townes, PhD, and K. Pawlik, PhD (University of Alabama, Birmingham), for kindly providing the authors with mice that express Hb C93 and C93A. The authors also wish to acknowledge L. McMahon, MD, and A. Akinbami (Boston Medical Center) for helping the authors to obtain blood from sickle cell disease patients. Structural biology resources were provided by a NIH Shared Instrumentation Grant S10-OD021756 and Virginia General Assembly Higher Education Equipment Trust Fund (HEETF) to Virginia Commonwealth University (M.K.S.). This work was supported by Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine, Harvard Medical School and Massachusetts General Hospital (A.N.), Sanofi innovation award program (iAwards, A.N.), NIH/NIMHD grant MD009124 (M.K.S. and O.A.), NIH/NIDDK grant DK082971 (D.B.B.), and funds from the Department of Anesthesia, Critical Care, and Pain Medicine at Massachusetts General Hospital (W.M.Z.).

■ REFERENCES

(1) Rees, D. C.; Williams, T. N.; Gladwin, M. T. Sickle-cell disease. Lancet 2010, 376, 2038–2031.
(2) Center for Disease Control and Prevention. https://www.cdc.gov/ncebdd/sicklecell/data.html (accessed on Jan 17, 2018).
(3) Bunn, H. F. Pathogenesis and treatment of sickle cell disease. N. Engl. J. Med. 1997, 337 (11), 762–9.
(4) Eaton, W. A.; Bunn, H. F. Treating sickle cell disease by targeting HbS polymerization. Blood 2017, 129, 2719–2726.
(5) Steinberg, M. H.; McCarthy, W. F.; Castro, O.; Ballas, S. K.; Armstrong, F. D.; Smith, W.; Ataga, K.; Swardlow, P.; Kutlar, A.; DeCastro, L.; Wacławiw, M. A. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell, A.; Follow-Up, M. S. H. P., The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.3 year follow-up. Am. J. Hematol. 2010, 85, 403–408.
(6) Steinberg, M. H.; Barton, F.; Castro, O.; Pegelow, C. H.; Ballas, S. K.; Kutlar, A.; Oringer, E.; Bellevue, R.; Olivier, N.; Eckman, J.; Varma, M.; Ramirez, G.; Adler, B.; Smith, W.; Carlos, T.; Ataga, K.; DeCastro, L.; Bigelow, C.; Saunthararajah, Y.; Teller, M.; Vichinsky, E.; Claster, S.; Shurin, S.; Bridges, K.; Wacławiw, M.; Bonds, D.; Terrin, M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and beneﬁts up to 9 years of treatment. JAMA 2003, 289, 1645–1651.
(7) Eaton, W. A.; Hofrichter, J. Sickle cell hemoglobin polymerization. Adv. Protein Chem. 1990, 40, 63–279.
(8) Akinsheye, I.; Alsultan, A.; Solovieff, N.; Ngo, D.; Baldwin, C. T.; Sebastiani, P.; Chui, D. H.; Steinberg, M. H. Fetal hemoglobin in sickle cell anemia. Blood 2011, 118, 19–27.
(9) Steinberg, M. H.; Lu, Z. H.; Barton, F. B.; Terrin, M. L.; Charache, S.; Dover, G. J. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997, 89, 1078–1088.
(10) Charache, S.; Dover, G. J.; Moyer, M. A.; Moore, J. W. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell disease. Blood 1987, 69, 109–116.
(11) Platt, O. S. Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 2008, 358, 1362–1369.
(12) Wong, T. E.; Brandow, A. M.; Lim, W.; Lottenberg, R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood 2014, 124, 3850–3857.
(13) FDA approved l-glutamine powder for the treatment of sickle cell disease. https://www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm566097.htm (accessed on Jan 17, 2018).

DOI: 10.1021/acs.molpharmaceut.8b00108

Mol. Pharmaceutics 2018, 15, 1954–1963
(14) FDA D.I.S.C.O.: γ-glutamine for sickle cell disease. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572213.htm (accessed on Jan 17, 2018).

(15) Nihara, Y.; Zerez, C. R.; Akiyama, D. S.; Tanaka, K. R. Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J. Lab. Clin. Med. 1997, 130, 83–90.

(16) Nihara, Y.; Zerez, C. R.; Akiyama, D. S.; Tanaka, K. R. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am. J. Hematol. 1998, 58, 117–121.

(17) Perutz, M. F. Structure and mechanism of haemoglobin. Br. Med. Bull. 1976, 32, 195–208.

(18) Perutz, M. F.; Wilkinson, A. J.; Paoli, M.; Dodson, G. G. The stereochemical mechanism of the cooperative effects in hemoglobin revisited. Annu. Rev. Biophys. Biomol. Struct. 1997, 27, 1–34.

(19) Oder, E.; Safo, M. K.; Abdulmalik, O.; Kato, G. J. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br. J. Haematol. 2016, 175, 24–30.

(20) Safo, M. K.; Kato, G. J. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol. Oncol. Clin. North Am. 2014, 28, 217–231.

(21) Nakagawa, A.; Lui, F. E.; Wassaf, D.; Yefidoff-Freedman, R.; Casalena, D.; Palmer, M. A.; Meadows, J.; Mozzarelli, A.; Ronda, L.; Abdulmalik, O.; Bloch, K. D.; Safo, M. K.; Zapol, W. M. Identification of a Small Molecule that Increases Hemoglobin Oxygen Affinity and Reduces SS Erythrocyte Sickling. ACS Chem. Biol. 2014, 9, 2318–2325.

(22) Huang, Z.; Shiva, S.; Kim-Shapiro, D. B.; Patel, R. P.; Ringwood, L. A.; Irby, C. E.; Huang, K. T.; Ho, C.; Hogg, N.; Schechter, A. N.; Gladwin, M. T. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J. Clin. Invest. 2005, 115, 2099–2107.

(23) Isbell, T. S.; Sun, C. W.; Wu, L. C.; Teng, X.; Vitturi, D. A.; Branch, B. G.; Kevil, C. G.; Peng, N.; Wyss, J. M.; Ambalavanan, N.; Schieweit, L.; Ren, J.; Pavlik, K. M.; Renfrow, M. B.; Patel, R. P.; Townes, T. M. SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation. Nat. Med. 2008, 14, 773–777.

(24) Montaguti, P.; Melloni, E.; Cavalletti, E. Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylfuranamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. Arzneimittel-Forschung 1994, 44, 566–570.

(25) Safo, M. K.; Abraham, D. J. X-ray crystallography of hemoglobinins. Methods Mol. Med. 2003, 82, 001–019.

(26) Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2011, 67, 235–242.

(27) Safo, M. K.; Burnett, J. C.; Musayev, F. N.; Nokuri, S.; Abraham, D. J. Structure of human carbonmonoxymoglobin at 2.16 Å: a snapshot of the allosteric transition. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2002, 58, 2031–2037.

(28) Park, S. Y.; Yokoyama, T.; Shibayama, N.; Shiroyama, T.; Yamae, T.; Tame, J. R. 1.25 Å resolution crystal structures of human hemoglobin in the oxy, deoxy and carbonmonoxy forms. J. Mol. Biol. 2006, 360, 690–701.

(29) Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Iorger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Saccchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2002, 58, 1948–1954.

(30) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2010, 66, 486–501.

(31) Abdulmalik, O.; Safo, M. K.; Chen, Q.; Yang, J.; Brugnara, C.; Ohene-Frempong, K.; Abraham, D. J.; Asakura, T. S-hydroxymethyl-2-furfural modifies intracellular sickle hemoglobin and inhibits sickling of red blood cells. Br. J. Haematol. 2005, 128 (4), 552–561.

(32) Hijjai, N.; Horuchi, K.; Asakura, T. Morphology of sickle cells produced in solution of varying osmolalities. J. Clin. Lab. Med. 1991, 117, 60–66.

(33) Benesch, R.; Benesch, R. Chemistry of Bohr Effect I. Reaction of N-Ethyl Maleimide with Oxygen-Linked Acid Groups of Hemoglobin. J. Biol. Chem. 1961, 236, 405–410.

(34) Goldstein, J.; Guidotti, G.; Konigsberg, W.; Hill, R. J. The amino acid sequence around the “reactive sulphhydryl” group of the beta chain from human hemoglobin. J. Biol. Chem. 1961, 236, PC77–PC78.

(35) Riggs, A. The binding of N-ethylmaleimide by human hemoglobin and its effect upon the oxygen equilibrium. J. Biol. Chem. 1961, 236, 1948–1954.

(36) Henderson, L. J. The equilibrium between oxygen and carbonic acid in blood. J. Biol. Chem. 1920, 41, 401–410.

(37) Perutz, M. F.; TenEyck, L. F. Stereochemistry of cooperative effects in hemoglobin. Cold Spring Harbor Symp. Quant. Biol. 1972, 36, 295–310.

(38) Riggs, A. The Nature and Significance of the Bohr Effect in Mammalian Hemoglobins. J. Gen. Physiol. 1960, 43, 737–752.

(39) Cheng, Y.; Shen, T. J.; Simplaceanu, V.; Ho, C. Ligand binding properties and structural studies of recombinant and chemically modified hemoglobinals altered at β93 cysteine. Biochemistry 2002, 41, 11901–11913.

(40) Kilmartin, J. V.; Fogg, J. H.; Perutz, M. F. Role of C-terminal histidine in the alkaline Bohr Effect of human hemoglobin. Biochemistry 1980, 19, 3189–3193.

(41) Perutz, M. F.; Kilmartin, J. V.; Nishikura, K.; Fogg, J. H.; Butler, P. J.; Rollema, H. S. Identification of residues contributing to the Bohr effect of human haemoglobin. J. Mol. Biol. 1980, 138, 649–668.

(42) Russu, I. M.; Ho, N. T.; Ho, C. Role of the β146 histidine residue in the alkaline Bohr effect of human hemoglobin. Biochemistry 1980, 19, 1043–1052.

(43) Garel, M. C.; Caburi-Martin, J.; Domenget, C.; Kister, J.; Crascu, C. T.; Poyart, C.; Beuzard, Y. Changes of polymerization and conformation of hemoglobin S induced by thiol reagents. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1990, 1041, 133–140.

(44) Antonini, E.; Condo, S. G.; Giardina, R.; Ioppolo, C.; Bertollini, A. The effect of pH and D-glycerate 2,3-bisphosphate on the O2 equilibrium of normal and SH(β93)-modified human hemoglobin. Eur. J. Biochem. 1982, 121, 325–328.

(45) Garel, M.; Beuzard, Y.; Thillet, J.; Domenget, C.; Martin, J.; Galacteros, F.; Rosa, J. Binding of 21 Thiol Reagents to Human-Hemoglobin in Solution and Intact-Cells. Eur. J. Biochem. 1982, 123, 513–519.

(46) Popp, R. A. Sequence of amino acids in the chain of single hemoglobins from C57BL, SWR, and NB mice. Biochim. Biophys. Acta, Protein Struct. 1973, 303, 52–60.